化学療法剤の適切な使い方について
|
|
- しげじろう こうい
- 7 years ago
- Views:
Transcription
1
2 5 6 7 Che E, in Cancer: Principles & Practice of Oncology (7th ed) in Devita, 2005 Marangolo M, Oncol Rep, 2006 hryniuk WM, Important Adv Oncol, Cancer: Principles & Practice of Oncology 5th Ed. Devita, 1997
3 9 Rassnick KM, Vet Comp Oncol, 2010 Vaughan A, JVIM, 2007 Frimberger AE, JVIM, IIIVn= 66 L-CHOP-CCNU-MOPP p= 0.05 L-CHOP Rassnick KM, Vet Comp Oncol, IIIVn= Vaughan A, JVIM, IIIVn= 28 VELCAP p= Frimberger AE, JVIM, 2006
4 13 14 CCNU (70mg/m 2 ) CCNU(60mg/m 2 ) CCNU (60mg/m 2 ) CCNU (60mg/m 2 ) SD PR CR Grade4 Seg= 37 Grade4 Seg= 34 Grade4 Seg= 251 Grade4 Seg= kg 16
5 17 Ogilvie GK, JAVMA, !20 PDGFR= VEGFR= PDGF PDGF & PDGFR-β binding VEGF PDGFR-β トセラニブ VEGF & VEGFR-2 binding VEGFR-2 トセラニブ
6 21 London CA, Vet Compar Oncol, n= 85 % n=32 n=23 n=15 n=8 n=7 London CA, Vet Compar Oncol, n= 85 London CA, Vet Compar Oncol,
7 25!26 27 Samm, 2010 Phillips, 2009 Kow, CI: -211 to -52) Boerman I, BMC Vet Res,
8 !29! Give Up? Yeah, used to be...!32 286
9 !33 363!34 412!35 440!36 475
10 !37 501! Lee KW et al., Cancer, 2003
11 41 Lee KW et al., Cancer,
12 45 46 n CR CR 9 50% 5 Jeglum KA, JAVMA, % 7.1 Mahony OM, JAVMA, Vail DM, JVIM, % 4.7 Zwahlen CH, JAVMA, % 8.2 Teske E, JVIM, % 34.8 Limmer S, VCO, % 1.7PFI Collette SA, VCO, 2015 * CHOP 47!48 n=20 Gouldin ED, VCO, 2015
13 49 Rassnick KM, JAVMA, Dank G, Vet Comp Oncol, % 1. Moore AS, J Vet Intern Med. 1990, 2. Chun R, J Am Vet Med Assoc. 1996, 3. Knapp DW, Cancer Chemother Pharmacol. 2000, 4. Chun R, Vet Intern Med. 1997, 5. Knapp DW, J Vet Intern Med. 1994, 6. Mutsaers AJ, J Vet Intern Med. 2003, 7. Knapp DW, J Vet Intern Med. 2013, 9. Arnold EJ, J Vet Intern Med. 2011, 12. Robat C, J Small Anim Pract. 2013, 13. Mohammed SI, Cancer Res. 2002, 14. Mohammed SI, Mol Cancer Ther. 2003, 15. Boria PA, Vet Comp Oncol. 2005, 16. Greene SN, J Am Vet Med Assoc. 2007, 18. Marconato L, J Am Vet Med Assoc. 2011, 19. Kaye ME, Vet Comp Oncol. 2013, 20. Schrempp DR, J Am Vet Med Assoc. 2013, 21. Henry CJ, Clin Cancer Res. 2003, 22. Knapp DW, Small Animal Clinical Oncology (5 th ed), 2013, 23. Perazella MA, Semin Nephrol. 2010, 24. Rao P, J Pharm Pharm Sci. 2008, 25. Allstadt SD, J Vet Intern Med 2015, 26. Knapp DW, ILAR J % 1. Moore AS, J Vet Intern Med. 1990, 2. Chun R, J Am Vet Med Assoc. 1996, 3. Knapp DW, Cancer Chemother Pharmacol. 2000, 4. Chun R, Vet Intern Med. 1997, 5. Knapp DW, J Vet Intern Med. 1994, 6. Mutsaers AJ, J Vet Intern Med. 2003, 7. Knapp DW, J Vet Intern Med. 2013, 9. Arnold EJ, J Vet Intern Med. 2011, 12. Robat C, J Small Anim Pract. 2013, 13. Mohammed SI, Cancer Res. 2002, 14. Mohammed SI, Mol Cancer Ther. 2003, 15. Boria PA, Vet Comp Oncol. 2005, 16. Greene SN, J Am Vet Med Assoc. 2007, 18. Marconato L, J Am Vet Med Assoc. 2011, 19. Kaye ME, Vet Comp Oncol. 2013, 20. Schrempp DR, J Am Vet Med Assoc. 2013, 21. Henry CJ, Clin Cancer Res. 2003, 22. Knapp DW, Small Animal Clinical Oncology (5 th ed), 2013, 23. Perazella MA, Semin Nephrol. 2010, 24. Rao P, J Pharm Pharm Sci. 2008, 25. Allstadt SD, J Vet Intern Med 2015, 26. Knapp DW, ILAR J. 2014
14 53 % 1. Moore AS, J Vet Intern Med. 1990, 2. Chun R, J Am Vet Med Assoc. 1996, 3. Knapp DW, Cancer Chemother Pharmacol. 2000, 4. Chun R, Vet Intern Med. 1997, 5. Knapp DW, J Vet Intern Med. 1994, 6. Mutsaers AJ, J Vet Intern Med. 2003, 7. Knapp DW, J Vet Intern Med. 2013, 9. Arnold EJ, J Vet Intern Med. 2011, 12. Robat C, J Small Anim Pract. 2013, 13. Mohammed SI, Cancer Res. 2002, 14. Mohammed SI, Mol Cancer Ther. 2003, 15. Boria PA, Vet Comp Oncol. 2005, 16. Greene SN, J Am Vet Med Assoc. 2007, 18. Marconato L, J Am Vet Med Assoc. 2011, 19. Kaye ME, Vet Comp Oncol. 2013, 20. Schrempp DR, J Am Vet Med Assoc. 2013, 21. Henry CJ, Clin Cancer Res. 2003, 22. Knapp DW, Small Animal Clinical Oncology (5 th ed), 2013, 23. Perazella MA, Semin Nephrol. 2010, 24. Rao P, J Pharm Pharm Sci. 2008, 25. Allstadt SD, J Vet Intern Med 2015, 26. Knapp DW, ILAR J
15 !57!58 60
16 61 Berg J, Cancer, n= 102) mg/m 2 IV 60mg/m 2 ) IV 23 x 3 Berg J, Cancer, n vs. P< vs. 10p=0.727 Berg J, Cancer, Berg J, Cancer, 1997
17 65 Berg J, Cancer,
分子標的薬アプデート 2018
Primary imatinib, 2002-2008 (CML IV) 5-year survival 93% n = 2830 Survival probability IFN or SCT, 1997-2008 (CML IIIA) 5-year survival 71% IFN or SCT, 1995-2008 (CML III) 5-year survival 63% IFN, 1986-2003
More information437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
More informationuntitled
2303 16 2 9 1 14 5 31 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2) 1487.47 11 2 1 4 104 2 14 5 31 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) 4. 1 2 1
More informationuntitled
( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m
More information1 2 3 6 10 < > 13 16 16 4 17 13 00 15 30 5
2004 16 3 23 q 4 21 r 1 2 3 6 10 < > 13 16 16 4 17 13 00 15 30 5 13 2 2 16 4 4 17 3 16 3 1 16 3 2 905 1438 1201 1205 1210 70 1812 25 1635 1654 3 44 47 10 10 911.18-R 1193 34 1652 4 911.107-H 1159 1685
More information日本皮膚科学会雑誌第122巻第2号
J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot
More informationuntitled
37 70,500 135,000 27,700 11 37,400 60,400 8,900 5 40,900 64,900 26,600 4 40,100 47,200 29,700 2 30,500 37,100 24,000 36 62,800 132,000 4,800 20 50,800 72,300 10,800 60 2 7 12 17 67,900 74,872 80,133 83,500
More informationPDF変換用(報告書)帯広市新エネルギービジョ
12 1 (260 3)(800 3 40 (800 3 1,300 3 ) 40 60 40 22 18 3738 1 10 1 2 11 5 24 12 8 1 2 15 () 3 26 3 13 6 8 12 3 70 4 16 1 6 4 12 9 30 6,000 70 3,500 5 1,000kw 20 45 27 100 12 11 11 20 1 45 17 11 60 6 20
More information日本皮膚科学会第121巻第9号
Appl Nurs Res Wound Repair Regen Int Wound J Adv Skin Wound Care Ostomy Wound Manage Wound Repair Regen Int J Nurs Stud JAdvNurs Visual Dermatology J Adv Nurs Appl Nurs Res Cochrane Database Syst Rev
More informationE3200 BV FOLFOX4 FOLFOX4 PFS % 0.42, 0.65 p< log-rank % FOLFOX4 8.6% FOLFOX % FOLFOX4 259/ % FOL
E3200 BV FOLFOX4 FOLFOX4 PFS 4.5 7.5 0.518 95% 0.42, 0.65 p
More informationuntitled
NPO 2006( ) 11 14 ( ) (2006/12/3) 1 50% % - - (CO+H2) ( ) 6 44 1) --- 2) ( CO H2 ) 2 3 3 90 3 3 2 3 2004 ( ) 1 1 4 1 20% 5 ( ) ( ) 2 6 MAWERA ) MAWERA ( ) ( ) 7 6MW -- 175kW 8 ( ) 900 10 2 2 2 9 -- - 10
More informationuntitled
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J
More informationSmall Animal Clinic C O N T E N T S NO.154 2 4 10 18 28 31 32 34 3 3 Small Animal Clinic No.154 4 5 Small Animal Clinic No.154 6 7 Small Animal Clinic No.154 8 9 Small Animal Clinic No.154 10 11 Small
More informationSmall Animal Clinic NO.146 C O N T E N T S 2 4 11 16 19 24 28 30 34 3 3 Small Animal Clinic No.146 4 5 Small Animal Clinic No.146 6 7 Small Animal Clinic No.146 8 9 11 Small Animal Clinic No.146 12 13
More informationSmall Animal Clinic C O N T E N T S NO.161 2 4 10 20 30 28 32 34 3 Small Animal Clinic No.161 4 5 6 Small Animal Clinic No.161 7 8 Small Animal Clinic No.161 9 Small Animal Clinic No.161 10 11 Small Animal
More information2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
More information物理化学I-第12回(13).ppt
I- 12-1 11 11.1 2Mg(s) + O 2 (g) 2MgO(s) [Mg 2+ O 2 ] Zn(s) + Cu 2+ (aq) Zn 2+ (aq) + Cu(s) - 2Mg(s) 2Mg 2+ (s) + 4e +) O 2 (g) + 4e 2O 2 (s) 2Mg(s) + O 2 (g) 2MgO(s) Zn(s) Zn 2+ (aq) + 2e +) Cu 2+ (aq)
More information特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
More information取扱説明書 [F-05E]
F-05E 12.11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 a b 22 c d e 23 24 a o c d a b p q b o r s e f h i j k l m g f n a b c d e f g h 25 i j k l m n o p q r s a X b SD 26 27 28 X 29 a b c
More informationスライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
More information空き容量一覧表(154kV以上)
1/3 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量 覧 < 留意事項 > (1) 空容量は 安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 熱容量を考慮した空き容量を記載しております その他の要因 ( や系統安定度など ) で連系制約が発 する場合があります (3) 表 は 既に空容量がないため
More informationAtlas_j060419
Hill s Atlas of Veterinary Clinical Anatomy 1 29 30 2 3 4 5 31 32 33 34 35 36 37 6 7 8 9 10 11 12 13 38 39 40 41 14 15 16 17 18 19 20 21 22 23 24 25 26 27 42 43 44 45 46 47 48 49 50 51 52 53 54 55 28 81
More information2/8 一次二次当該 42 AX 変圧器 なし 43 AY 変圧器 なし 44 BA 変圧器 なし 45 BB 変圧器 なし 46 BC 変圧器 なし
1/8 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( や系統安定度など ) で連系制約が発生する場合があります (3)
More information終末期の呼吸困難症状への対応*松坂最終修正
Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,
More information日本皮膚科学会雑誌第121巻第11号
β Clin Rheumatol Arthritis Rheum Am J Cardiol J Rheumatol J Rheumatol Arthritis Rheum Arthritis Rheum Arthritis Rheum Rheumatology Oxford Rheumatology Oxford Br J Dermatol Arch Dermatol Ann Rheum Dis
More informationMicrosoft Word - ゴールドコーストマラソン2014.docx
2014 2014 7 3 7 14:25 16:20 22:25 6:25 10:55 19:00 22:55 0:35 42.195Km 7,300km 537,844 2013 6 30 6 2 1 Dr. 1 20 10 Q1 Q1 8m 2 7 4 15 J B H..S 45 30 7 20 49 20 15 3 45 4 3 50 28 35 km 40km 4 4 6 15km 20km
More informationCRA3689A
AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF
More informationRinku General Medical Center
Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines
More information19 3 6 4 65 50 2 1 25.018.716.2 15.0 7 70.17.9 8 44.242.3 50.6 5 23.3 35.7 2 1 (SA) 2 (SA) 6 4 3 (SA) PTA 4 (SA) 7 50 5 (SA) 4 6 (3 ) 7 (SA) 8 2 1 8 3 30 50 9 (SA) 5 60 10 (SA) 2 11 (SA) 12 (MA) 40 13
More information<30332D D8CB492982D FC95E490E690B62D8FAC8FBC96BE90E690B62E706466>
A questionnaire survey on the use of placebo in clinical practice by nurses in Japan 1 1 2 2 1 4 1964 5, 6 1998 GCP 1 School of Nursing, Faculty of Medicine, Toho University 2Faculty of Medical Technology,
More informationCAR-T実施
Building a Clinical CAR-T Program - Jichi Medical University Experience l l l Anti-CD3/28 mabs & IL-2: 29% Anti-CD3/28 beads: 66% Retroviral: 41% Lentiviral: 54% T-Flasks: 22% Static Culture Bags: 35%
More information32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
More information1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です
8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%
More informationVOL33NO.3/2010 A B A B p-erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 Erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 p-vasp VASP C D enos/gapdh x-fold vs sham 2.0 1.5 1.0 0.5 * 0 ANP (-) (+) (-)
More informationDM
( ) FAX DM DM PR 300 - - - - - - - - - - - - - - - - - - 6 3 1 4 3 - - - - PR P173 FAX (2001) (2000) (1999) 1986 http://kimono-yamato.com/04-kiso/qa.html Q&A http://web.sfc.keio.ac.jp/~t00524sh/chousa/rich/kimonobegin.html
More information<90CE90EC88E290D55F955C8E862E656336>
5 5 9 9 7 7 5 5 6 6 7 7 8 8 9 9 8 8 8 8 79 79 78 78 76 76 77 77 7 7 6 7 7 5 68 68 67 67 66 66 65 65 6 6 6 6 6 6 6 6 6 6 59 59 58 58 57 57 56 56 55 55 5 5 8 8 5 5 9 9 9 8 7 9 9 8 8 7 7 6 6 5 5 5 5 69 69
More informationThe Heart Healthy Tocotrienol Complex Tocomin SupraBio
The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio 1. Fact Sheet No. 317; World Health Organization (WHO), 2007 2. LLOYD-JONES D. et al. Circulation
More informationⅡ 本編 19 1 23 1-1 - 16 - - 17-1-3 1-2 - 18 - - 19 - - 20 - - 21 - - 22 - 3 10 60 1,000 3,000-24 - 23.9% 19.2% 16.6% 37.4% 32.3% - 25 - 300500 27.6% 500700 21.0% 300 20.2% 7001,000 17.9% 1,000 13.3% 2-1-6-26
More information10 2 2 10 6.5 78 1 65 / 30 / - 2 -
- 1 - 10 2 2 10 6.5 78 1 65 / 30 / - 2 - 3 3 30 8 4 8 6 11 14 45 14 7 8 1-3 - 4 1 () 20 4 9 4 9 3 9 4 PR 4 3-4 - - 5 - PR 15 4 PR 7 8 4 9 10-6 - 9 10 9 10 4 9 10 3 9 10 9 9 9 10 PR 1-7 - PR - 8 - 30 100-9
More information10K1A NASA () SPACE ATLAS Freedom H2A NASA 1
10O1A 10 10 1 10K1A NASA () SPACE ATLAS 40 1957 1969 10 1986 1990 Freedom 20 000 H2A NASA 1 10K1A 100 10 21 40 1996 ( 200 () 2 10S1A 10 8 57 250 1 10S1A 20 200mmm 2 10S1B 18 18 1 10S1B 40 10 20 2 10S1C
More informationuntitled
19 11 13 300 18 3 31 1300mg 4 6 C 15 H 22 FN 3 O 6 359.35 + -1-5--β-D--5--1,2--2- -4- 19 11 13 300 18 3 31 A B B A 30 1 2 21 7 1 1 1.31m 2 900mg 1.31m 2 1.64m 2 1,200mg 1.64m 2 1,500mg B 30 1 2 14 7 1
More information卵巣癌の治療
K-net:2008.7.17 85 90 8 10 20 (FIGO) a (FIGO) b (FIGO) c (FIGO) a (FIGO) b (FIGO) c (FIGO) (FIGO) (FIGO) Risk factors Preventive factors Risk factors 35 PCO, Preventive factors? Relative risk
More information1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載
1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( 電圧や系統安定度など ) で連系制約が発生する場合があります
More information1 2 1 3 2 4 22 NPO PR NPO NPO 22 10 4 2,000kg 1kg 5 2 1 4,000 20,000 26 33 27 24 3 19 24 3 4 3 4 3 () 34 3 4 5 23 3 17 23 20 30 1 1 877g/ 3 24 3 1 1 28 897g/ 33 850g/ 22 23 30 1 1 510g/ 22 23 3 24
More information取扱説明書
ED-601 ED-501 ED-401 2 3 4 23 14 5 6 18 10 7 1 2 6 3 4 8 9 16 16 16 12 1 2 18 10 2 1 5 12 11 1 2 1 2 12 1 2 13 16 14 3 2 4 1 1 2 16 3 4 18 15 1 2 16 2 3 1 1 2 3 18 17 18 22 19 D A C 20 A B 22 B C D 22
More information橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
More informationVarious function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,
More information3675-433897418-1.pdf
A : : : : : : : : : : PR PR NHK 2 PR PR 3 1954 7 4 5 9 12,000 12 100 2 2 11 4 5 6 7 / PR 8 9 10 11 1952 ( ) 2008 2009 2012 NHK km m m 12 m km km kg kg 13 % 14 15 1959 5 20 8 17100kg 400kg How much? 60
More information近畿中国四国農業研究センター研究報告 第7号
230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15
More information肺癌第50巻第4号
1 Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan; 2 Department of Thoracic Surgery, Aichi Cancer Center, Japan;
More information42 3 u = (37) MeV/c 2 (3.4) [1] u amu m p m n [1] m H [2] m p = (4) MeV/c 2 = (13) u m n = (4) MeV/c 2 =
3 3.1 3.1.1 kg m s J = kg m 2 s 2 MeV MeV [1] 1MeV=1 6 ev = 1.62 176 462 (63) 1 13 J (3.1) [1] 1MeV/c 2 =1.782 661 731 (7) 1 3 kg (3.2) c =1 MeV (atomic mass unit) 12 C u = 1 12 M(12 C) (3.3) 41 42 3 u
More informationライフサイエンス関連 コラーゲン・ゼラチン製品案内 2015.12
3 mg/ml ph 3 4 8 1 Type I-A Type I-P Type I-A Type I-C Type III Type III Type IV Type IV TEL 072-820-3079 FAX 072-820-3095 4 8 4 Type I-A 20mL 1 F-12 MEM 5mL 1 4mL 5 10F-12MEM DFDME F-12 1 1199 5 DMERPMI-1640
More information, ,
41 42 73 121 121 10 122 11 122 12 131 13 131 15 10 133 16 11 133 17 12 136 18 13 141 19 14 141 20 15 146 21 16 149 22 17 149 23 174 18 24 73 19 241,301 25 20 242,301 (1) 26 21 331 27 22 241,341 28 23 242,341
More information【知事入れ版】270804_鳥取県人口ビジョン素案
7 6 5 4 3 2 1 65 1564 14 192 193 194 195 196 197 198 199 2 21 22 23 24 1.65 1,4 1.6 1,2 1.55 1, 1.45 6 1.5 8 1.4 4 1.35 1.3 2 27 28 29 21 211 212 213 214 6 5 4 3 2 1 213 218 223 228 233 238 243 248 253
More information表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
More informationO-1 O-2 O-3 O-4 O-5 O-6
18 The 18 th Congress of Hokkaido Association for Clinical Engineering Technologists 930940 O-1 O-2 O-3 O-4 O-5 O-6 O-7 O-8 O-9 O-10 O-11 O-12 O-13 O-14 O-15 O-16 O-17 O-18 O-19 O-20 O-21 O-22 O-23 O-24
More informationiii iv v vi 21 A B A B C C 1 1 2 3 4 5 6 1 2 3 4 5 6 7 8 9 10 11 19 22 30 39 43 48 54 60 65 74 77 84 87 89 95 101 12 20 23 31 40 44 49 55 61 66 75 78 85 88 90 96 102 13 21 24 32 41 45 50 56 62 67 76 79
More informationJA2008
A1 1 10 vs 3 2 1 3 2 0 3 2 10 2 0 0 2 1 0 3 A2 3 11 vs 0 4 4 0 0 0 0 0 3 6 0 1 4 x 11 A3 5 4 vs 5 6 5 1 0 0 3 0 4 6 0 0 1 0 4 5 A4 7 11 vs 2 8 8 2 0 0 0 0 2 7 2 7 0 2 x 11 A5 9 5 vs 3 10 9 4 0 1 0 0 5
More information1
I II II 1 dw = pd = 0 1 U = Q (4.10) 1K (heat capacity) (mole heat capacity) ( dq / d ) = ( du d C = / ) (4.11) du = C d U = C d (4.1) 1 1 du = dq + dw dw = pd dq = du + pd (4.13) p dq = d( U + p ) p (4.14)
More informationJuntendo Medical Journal
The hair growth effect of minoxidil Susumu OTOMO, Ph. D. Key words : minoxidil, minoxidil sulfate, hair growth, K+-channel opener, male pattern baldness Dept. of Pharmacology, Research Center Taisho Pharmaceutical
More information(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12
(1)...109 (2)...110 (1) 28...111 (2) 28...113 (1) Seg...115 (2) Seg...117 (3) Seg...119 (4) Seg...120 (1)...122 (2)...122 (3) ( )...126 (1) (PCA)...127 (2) Draize...128 (1) Ames...129 2 in vitro...132
More information1 509 12kg 1 ( ) L 9/19 6 00 SA8 20---8 30 PA10 30 IC12 30 12 40 13 12 14 00 15 40 9/20 4 00--- 5 30--- 6 20 7 00-8 00---8 15 9 20 7 9 45---10 00 10 40--- 11 00 11 45---11 55 12 20---12 35 13 20 14 40
More information野岩鉄道の旅
29th 5:13 5:34 5:56 6:00 6:12 6:20 6:21 6:25 6:29 6:31 6:34 6:38 6:40 6:45 6:52 6:56 7:01 7:07 7:11 7:32 7:34 7:50 7:58 8:03 8:17 8:36 8:44 5:50 5:54 6:15 6:38 6:39 6:51 6:59 6:59 7:03 7:08 7:08 7:11 7:15
More information1
1 5% 4% 11% 8% 13% 12% 10% 6% 17% 6% 8% 4% 6% 6% 2% 17% 17% 12% 14% 16% 6% 37% 11% 17% 35% 2 (N=6,239) 0 200 400 600 800 1,000 1,200 1,400 1,600 1,800 1,585 1,126 950 494 345 296 242 263 191 150 131 116
More information慢性膵炎
- - 121 , g CCK g g - kgkcal kgkcal - g,,, - G.I.Res ; 10 : - ; 13 : - ; 22 : - Meier RF, Beglinger C. Nutrition in pancreatic diseases. Best Pract Res Clin Gastroenterol ; 20 : - Pfutzer RH, Schneider
More information37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
More information77 http//www.pref.nara.jp/rinsei/bio/biotop.htm 1... 1 2... 2 3... 3 4... 4 5 1... 5 6 2... 6 7 3... 7 8 4... 8 9... 9 1... 1 11... 12 12... 14 13... 16 14... 18 15... 2 16... 22 17 1... 24 18 2... 26
More informationuntitled
...1...5...7...10...13...15...18...20...23...26...28...30...32...34...36...38...40...42...44...46...48...50...52...53...54...55...57...59...61...63...63...65 ()...67...69...71...73...75...77 ...79...81...83...85...87...89...92...95...97...99...101...103...105...107...109...
More information1 2030 2 3 2030 2030 3 10,000 4 2010 9 27 10 18 5 6 100 7 3 20 30 20 30 30 30 2 8 31.6 30.7 22.6 15.0 29.7 29.7 23.6 17.0 45.2% n=10000 54.8% 33.9 31.9 21.5 12.7 9.7 2024 3034 2529 3539 19.0% n=10000 n=10000
More information土砂流入対策実施計画〔久著呂川〕
22 52 12 3000 2500 2000 1500 (km 2 ) 1000 500 0 1947 1955 1977 1985 1989 1994 2000 22 30 52 60 6 12 2000 1947 2000 110 100 90 (km 2 ) 30 20 10 1947 2000 0 () ( 10 20 () 30 40 50 60 60 a b b
More information36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
More information2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1
Mg-LPSO 2566 2016 3 2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1 1,.,,., 1 C 8, 2 A 9.., Zn,Y,.
More informationuntitled
twatanab@oncoloplan.com http://www.oncoloplan.com I II - III IV Fig 3. Survival curves overall and according to response Bruzzi, P. et al. J Clin Oncol; 23:5117-5125 25 Copyright merican Society of Clinical
More information